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Elevated glucose stimulates TGF-/3 gene expression and
bioactivity in proximal tubule
MICHAEL V. RoCco, YING CHEN, STANLEY GOLDFARB, and FUAD N. ZIYADEH
Renal-Electrolyte Section, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6144,
USA
Elevated glucose stimulates TGF.JJ gene expression and bioactivity in
proximal tubule. Our previous studies have demonstrated that raising
ambient glucose from 100 to 450 mg/dl significantly inhibited the
proliferation of mouse renal proximal tubule cells in culture. This effect
was demonstrated after a latent period of 24 to 48 hours. Because
transforming growth factor-beta (TGF-J3) inhibits cell proliferation in
most epithelial cell lines, we hypothesized that the inhibitory effect of
high glucose levels on cell proliferation may be mediated by TGF-/3.
The present studies were performed to test the hypothesis that TGF-/3
is an autocrine cytokine whose activity can be modulated by ambient
glucose. Exogenous TGF-13 inhibited [3H]-thymidine incorporation in a
dose-dependent fashion and with high affinity (picomolar range), but
with slightly lower potency in high versus normal glucose media.
Northern analysis of mRNA demonstrated that proximal tubule cells
constitutively express TGF-/31 transcripts, and that the steady state
level of TGF-p1 mRNA was, on average, 63% higher in the cells grown
for 48 hours in high versus normal glucose media. Furthermore, the
conditioned media of cells exposed to 450 mg/dl glucose exhibited
endogenous TGF-13 bioactivity as measured by inhibition of cell prolif-
eration. The addition of a rabbit antiporcine TGF-13 neutralizing anti-
body significantly increased basal thymidine incorporation in high
glucose media to levels approaching those of cells grown in normal
glucose media. In contrast, the anti-TGF-j3 antibody did not have a
significant effect on the growth of cells in the normal glucose media.
Control rabbit IgG did not stimulate growth. We conclude that TGF-/3
functions as an autocrine cytokine in proximal tubule cells and that
expression of TGF-/3 is stimulated by high glucose concentration. The
growth inhibitory effect of elevated glucose levels may be largely
mediated by increased endogenous TGF-/3 production and/or activity.
Transforming growth factor-beta (TGF-/3) is a highly con-
served cytokine that is ubiquitous in living organisms. TGF-13
and its receptors are located in virtually all organ systems
studied, including the kidney [1—4], and TGF-/3 can act in either
an autocrine or paracrine fashion to influence a multitude of
cellular functions [5].
TGF-f3 has a particularly crucial role in regulating cell growth
as it inhibits the proliferation of most epithelial cell types in
culture, as well as of mesenchymally derived lymphocytes and
vascular endothelial cells [5]. In fibroblasts, TGF-f3 can be
growth stimulatory or inhibitory, depending upon the presence
of other specific growth factors or on the developmental stage
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of the cell [6]. TGF-13 inhibits cell proliferation in most renal cell
lines examined, including glomerular mesangial, epithelial and
endothelial cells [5], in proximal tubule cells [7] and African
green monkey kidney epithelial (BSC-1) cells [8].
TGF-/3 also stimulates matrix synthesis, inhibits matrix deg-
radation and stimulates the synthesis of receptors for matrix
proteins [9], and can induce increased synthesis of the proteo-
glycans biglycan and decorin [10, 11], and of collagen IV,
laminin and fibronectin in glomerular cells [11—13]. Because of
these effects on cell matrix, recent studies have focused on the
potential role of TGF-/3 in renal fibrogenesis. In experimental
models of glomerular injury, TGF-/3 has been implicated in the
genesis of renal fibrosis caused by the administration of anti-
glomerular basement membrane antibody [14] and of glomeru-
lonephritis induced by antithymocyte serum [15].
In an effort to explore some aspects of the pathobiology of the
renal tubulointerstitium in diabetes mellitus, we have recently
developed an in vitro model of diabetic renal disease using
murine proximal tubule cells in culture. We have demonstrated
that high glucose levels induce cell hypertrophy and collagen
transcription and secretion [16] while concurrently inhibiting
proliferation of proximal tubule cells. These effects of high
glucose levels are reminiscent of those induced by TGF-/3 on
epithelial cells. We therefore postulated that at least some of the
effects of high glucose media may be caused by the endogenous
production of TGF-/3 by the proximal tubule cells. In this study,
we demonstrate that TGF-/31 mRNA is constitutively expressed
in proximal tubule cells and we provide evidence that the
reduction of proximal tubule cell proliferation, which is induced
by elevated glucose levels, is largely mediated by increased
endogenous TGF-13 production and/or activity.
Methods
Cell culture
The cell line designated MCT (mouse cortical tubule) was
derived from kidneys of normal SJL mice. Proximal tubule cells
were selected by immunodissection using specific antibodies
against the 3M-l glycoprotein, a target antigen for autoimmune
interstitial nephritis [17]. These cells were virally transformed
with a non-replicating, non-capsid forming strain of SV-40. By
microscopy, the cells demonstrate many characteristics of
proximal tubule cells including positive staining for alkaline
phosphatase and cytokeratin, and surface projections on elec-
tron microscopy consistent with brush border villi. Details of
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the isolation and characterization of these cells have been
previously described [181.
Cells were incubated in a humidified atmosphere of 5% CO2
at 37°C. The cells were passaged every 48 to 72 hours and were
carried in RPMI 1640 media with a D-glucose concentration of
200 mg/dl and supplemented with 10% inactivated fetal calf
serum, 5 x 10 M hydrocortisone, 10 ms HEPES buffer, 24
m sodium bicarbonate, 5 g/ml insulin, 5 g/ml transferrin, 2
mM L-glutamine, 100 U/ml penicillin and 100 gJm1 streptomy-
cm.
Thymidine incorporation
Ten thousand MCT cells per well were subcultured in flat-
bottomed 96-well plastic plates (Nunclon, Denmark) each con-
taining 200 l of a 1:1 mixture of serum-free Ham's F12 nutrient
medium and Dulbecco's modified Eagle medium (DMEM) to
give a final glucose concentration of 315 mg/dl. After 24 to 48
hours of quiescence, the media were removed and 200 d of
fresh serum-free DMEM with a D-glucose concentration of
either 100 mgldl (5.6 mM) or 450 mgldl (25 mM) were added to
each well. The DMEM was supplemented with penicillin and
streptomycin (as above) and with 2 g/ml transferrin and 2 mr't
glutamine. Some wells also received TGF-f31 (from porcine
platelets, R & D Systems, Minneapolis, Minnesota, USA),
neutralizing rabbit antiporcine TGF-f3 antibody (IgG fraction;
binds to the active forms of both TGF-f31 and TGF-/32; R & D
Systems), normal rabbit IgO (Sigma Chemical Co., St. Louis,
Missouri, USA) or rabbit anti-sheep IgG (Zymed, San Fran-
cisco, California, USA). The cells were grown for an additional
24 to 72 hour period (40 to 80% subconfiuence), and during the
last six hours of culture, they were pulsed with 1 Ci/wel1 of
[3H]-thymidine (5 Ci/mmol; Amersham, Arlington Heights,
Illinois, USA). The cells were collected with a cell harvester
(M-24S, Brandel, Gaithersburg, Maryland, USA) onto glass-
microfiber filter paper (934-AH, Whatman, UK). The radioac-
tivity was assayed by counting filters in scintillation fluid for
f3-emissions. [3H]-thymidine incorporation into cell DNA, ex-
pressed in counts per minute, was used as an index of cell
proliferation. Each experimental condition was tested in four to
eight replicate wells and the mean was taken to represent an
individual experiment.
Northern blot analysis
For each condition, 2 x 106 MCT cells in serum-free culture
medium were plated into a 75-cm2 plastic flask (Falcon, Lincoln
Park, New Jersey, USA). After 48 hours, the media were
replaced with fresh serum-free DMEM containing either 100
mg/dl or 450 mgldl of D-glucose. The cells were grown for an
additional 24, 48 or 72 hours and then were lysed and denatured
by adding to the flasks 4 M guanidinium thiocyanate, 25 mri
sodium citrate (pH 7.0), 0.5% sarcosyl and 0.1 M 2-mercapto-
ethanol. Total RNA was then extracted by phenol-chloroform
according to Chomczynski and Sacchi [19]. In some experi-
ments, poly (A)-enriched RNA from MCT cells was extracted
directly using the Fast Track mRNA isolation kit (Invitrogen,
San Diego, California, USA). Ten to 20 g of total RNA or 2 to
8 jg of poly(A)-RNA, as determined by UV spectropho-
tometry, was electrophoresed through a 1.0% agarose gel with
2.2 M formaldehyde.
RNA transfer to positively charged nylon membranes (Zet-
abind, CUNO Laboratory Products, Meriden, Connecticut,
USA) was performed by electroblotting (Horizontal Blotting
System, IBI, New Haven, Connecticut, USA) followed by
short wave UV crosslinking (UV Stratalinker, Stratagene, La
Jolla, California, USA). Prehybridization was performed for
two hours at 42°C using a prehybridization buffer composed of
5x SSPE (lx contains 149 ms NaC1, 10 ms NaH2PO4, 1 mM
EDTA), 5x Denhardt's solution (lx contains 0.1 g Ficoll, 0.1 g
polyvinylpyrrolidone, 0.1 g bovine serum albumin and H20 to
500 ml), 0.1% sodium dodecyl sulfate (SDS), 100 g/ml of
denatured, sheared salmon sperm DNA, and 50% (vollvol)
formamide. Hybridization was conducted for 20 hours at 42°C
using excised eDNA inserts as probes labeled with [32P]-dCTP
(>3000 Cilmmol) by the random hexamer priming technique
[20]. The hybridization buffer was similar to that used for
prehybridization except for the use of 2x Denhardt's solution.
The cDNA probes used were a 1.04 kb EcoRl fragment
encoding the human TGF-J31 gene from pSP64 (from Dr. A.
Singh, Genentech, San Francisco, California, USA) and a 1.3
kb PstI fragment encoding the rat glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) gene. After hybridization, the mem-
branes were washed in 2x SSC (lx SSC is 0.15 M sodium
chloride and 0.015 M sodium citrate, adjusted to pH 7.0) with
0.1% SDS for 30 minutes at room temperature, followed by
0.lx SSC with 0.1% SDS at 62°C for 15 minutes twice. The
membranes were then exposed to X-ray film (Kodak XAR-S
film) between two intensifying screens at —70°C for three to
seven days (TGF-13) or one to three days (GAPDH). Relative
mRNA levels were determined by densitometric scanning
(Hoefer Scientific Instruments, San Francisco, California,
USA) followed by area integration. The filters were first probed
with the TGF-f3 cDNA. To account for variations in RNA
loading, the filters were subsequently stripped for one to two
hours at 65°C with a solution containing 5 mrs Tris, 0.2 mM
EDTA (pH 8.0) and 5% sodium pyrophosphate in order to
remove the signal. The filters were then rehybridized with the
GAPDH eDNA probe.
Dot-blot hybridization
For dot-blot hybridization, MCT cells were cultured in flasks
as described above. The cells were grown for 24 to 72 hours in
media containing either 100 mgldl or 450 mg/dl of D-glucose,
then were released with a trypsin-EDTA mixture, washed twice
in PBS and counted in a Coulter cell Counter (Coulter Elec-
tronics, Hialeah, Florida, USA). The cells were lysed with 0.5%
NP-40 in Tris-EDTA buffer. Four times l0 cell equivalents of
cytoplasmic RNA were denatured with 40% formalin in 12x
SSC at 65°C for 15 minutes. The samples were then centrifuged
and the supernatants spotted onto Zetabind filters using a
hybridot apparatus (Bethesda Research Laboratories, Be-
thesda, Maryland, USA). In parallel experiments, additional
blots were obtained by using serial dilutions of measured RNA
(2.5 to 10 g per dot) which had been extracted as described
above [19]. The blots were dried, then prehybridized at 42°C for
16 hours in fluid containing 0.5 M phosphate buffer at pH 7.2,
150 g/ml Poly A, 150 j.g/ml denatured, sheared salmon sperm
DNA, 7% SDS, 1% bovine serum albumin and 1 mM EDTA.
Hybridization was performed in fluid containing [32P1-labeled
cDNA probes for TGF-13 and, after stripping, for GAPDH. The
filters were washed twice with 3 x SSC, 0.5% SDS at 55°C for 15
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TGF-3 concentration, -log M
Fig. 1. Effect of exogenous TGF-/3 on mouse proximal tubule (MCT)
cell proliferation as measured by tritia ted thymidine incorporation.
MCT cells were exposed to serum-free DMEM containing either 100
(open symbols) or 450 mgldl D-glucose (closed symbols) for a total of 72
hours. In the absence of TGF-j3 (C), thymidine incorporation in 450
mg/dl glucose was significantly lower (P < 0.001) than in 100 mg/dl
glucose. TGF-/3 was added at the indicated doses for the last 24 hours
of culture. Values are expressed as the mean SE; N = 8 replicates.
minutes, and once with 0.lx SSC, 0.1% SDS at 62°C for 15
minutes, then autoradiographed as described above. Relative
mRNA levels for TGF-/31 were determined as the ratio of the
densitometric signal for TGF-/31 mRNA to the corresponding
signal for GAPDH mRNA. For cells cultured in 100 mgldl of
D-glucose this ratio was assigned a value of unity.
Statistics
The mean for the replicates of each experiment was deter-
mined. The data are presented as the mean SE with N
indicating the number of experiments. Comparison between
two groups was performed using the paired or unpaired t-test,
as appropriate. Statistical significance was defined as a P <
0.05.
Results
Effects of glucose on cell proliferation
In our previous study [16], we demonstrated that the concen-
tration of glucose in serum-free culture medium induces a time
and dose dependent inhibition of proliferation of proximal
tubule cells. Thymidine incorporation of cells grown in 450
mg/dl glucose was reduced, on average, by 14%, 26% and 33%
after 24, 48 and 72 hours, respectively. Inhibition of cell
proliferation was confirmed when cell number was also deter-
mined. Moreover, growth inhibition was specific for D-glucose
and was not related to an effect of high osmolarity per se; the
addition of either L-glucose or D-mannitol did not have any
significant effect on cell proliferation [16]. In the current study,
a glucose-induced inhibition of cellular proliferation was con-
firmed. For example, Figure 1 demonstrates that the basal level
of thymidine incorporation of cells cultured in 450 mg/dl glucose
for 72 hours was reduced by 29% in the high versus the normal
glucose medium (P <0.001, N 8).
1.3kb
(GAPDH)
24hr 48hr
Fig. 2. Northern blot analysis of MCT mRNA hybridized with a human
cDNA probe for TGF-$1. A. Representative blot demonstrating consti-
tutive expression of TGF-131; 4 tg of poly(AY-RNA was isolated from
cells cultured for 72 hours in serum-free DMEM containing 100 mg/dl
D-glucose. The single band corresponds to the 2.5-kb TGF-13 mRNA.
B. For each condition, 10 .tg of total RNA was extracted from proximal
tubule cells cultured for 24 or 48 hours in serum-free medium containing
100 mg/dl or 450 mgldl of D-glucose. The RNA was loaded onto an
agarose gel, electrophoresed and transferred by electroblotting to a
nylon membrane. The band depicted in the upper panels is of the
predicted size for the TGF-131 transcript. The band depicted in the lower
panels was obtained by stripping the filter and reprobing with the
GAPDH probe. Arrows indicate the location of the 18 S and 28 S
ribosomal RNA. Conditions were as follows: lane 1: 24 hours, 100 mg/dl
D-glucose; lane 2: 24 hours, 450 mg/dl D-glucose, lane 3: 48 hours, 100
mg/dl D-glucose; lane 4: 48 hours, 450 mg/dl D-glucose.
Effect of TGF-p on cell proliferation
When TGF-131 was added in the final 24 hours of culture to
cells exposed for a total of 72 hours to either 100 or 450 mg/dl
glucose, it produced a dose dependent inhibition of tritiated
thymidine incorporation (Fig. 1). The half maximal inhibition of
proliferation by TGF-/3 was approximately 20 M and 30 p in
the normal and high glucose media, respectively. Note that with
increasing concentrations of TGF-13, the difference in thymidine
incorporation between the two cell populations became pro-
gressively smaller. In other experiments (not shown), the
inhibitory effect of TGF-/3 on proliferation persisted following
its addition for 48 or 72 hours. This inhibition also could be
prevented with cotreatment with either 2 jxg/ml insulin or 2
ng/ml epidermal growth factor (EGF) (data not shown). These
peptides are known mitogens in proximal tubule cells [7, 21].
TGF-f3 expression in proximal tubule cells
By Northern blot analysis, using a human cDNA probe for
TGF-f3, it was found that proximal tubule cells constitutively
express the predicted 2.5 kb mRNA for TGF-/3 (Fig. 2A). This
result raised the possibility that TGF-/31 may serve as an
autocrine factor in proximal tubule cells. Furthermore, we
postulated that the observed decrease in cell proliferation in
cultures containing 450 mgldl D-glucose may be attributed to
the increased production of TGF-/3 by the cells. To test this
hypothesis, we first examined whether high glucose levels
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stimulated endogenous TGF-f3 production by MCT cells. Rela-
tive TGF-/31 mRNA levels were thus determined in MCT cells
grown in media with a D-glucose concentration of either 100
mg/dl or 450 mg/dl. Figure 2B demonstrates that cells grown for
48 hours in high glucose media expressed levels of TGF-f31
mRNA, standardized to GAPD}1 mRNA levels, that were
approximately twice as high as those in cells grown in normal
glucose concentration. This response to high glucose medium
became apparent at 48 hours of culture (Fig. 2B), and was less
pronounced at 72 hours (data not shown). For further relative
quantification of mRNA levels, a series of dot-blot RNA
hybridizations were performed (Figure 3). The glucose-induced
stimulation in transcript levels at 48 hours varied between 36%
and 104% among different experiments (N = 4). The average
increase in TGF-J3 mRNA in high glucose medium was 63%
above the level in normal glucose medium. This conclusion was
valid whether comparisons were made on blots of equal quan-
tities of RNA (Fig. 3) or on RNA extracted from equal numbers
of cells (data not shown).
Effect of TGF-13 neutralizing antibody on cell proliferation
A TGF-/3 neutralizing antibody was used as a functional
assay for endogenous TGF-13-like activity in the conditioned
media. We initially confirmed that this antibody (IgG fraction of
antiserum) exhibited a neutralizing effect on TGF-13 action. As
shown in Figure 4, the reduction in thymidine incorporation
produced by exogenous TGF-/3 (40 pM) can be largely pre-
vented by the addition of 30 g/ml anti-TOF-/3 antibody. In this
set of experiments, "control" cells were cultured in 450 mg/dl
glucose without the addition of TGF-f3. Rabbit anti-sheep IgG
added as a control had no effect on thymidine incorporation. In
other experiments (not shown) the neutralizing property of
anti-TGF-fl antibody to exogenously added TGF-/3 was also
demonstrable when the cells were grown in 100 mgldl glucose.
The addition of 30 g/ml of anti-TGF-J3 antibody in high
glucose media increased basal thymidine incorporation of these
cells to levels which approximate the basal incorporation of
thymidine in cells grown in normal glucose media (Fig. 5), The
addition of anti-TGF-f3 antibody to cells raised in normal
glucose media, however, had no significant effect on ['H]-
thymidine incorporation. As a control, normal rabbit non-
immune IgG (30 jsglml) had no significant effect on cell prolif-
eration in either high or normal glucose media (Fig. 5). Similar
results were obtained when a lower dose of anti-TGF-/3 anti-
body (10 pgIml) was employed in an additional set of six
different experiments (Fig. 6). As a control, a rabbit anti-sheep
IgG was used in these studies. In normal glucose media, the
addition of either anti-TGF-/3 antibody or rabbit anti-sheep IgG
(10 p/ml) had no significant effect on basal ['H]-thymidine
incorporation. In high glucose media, however, the addition of
anti-TGF-J3 antibody, but not the control rabbit anti-sheep IgG,
resulted in a 30% increase in thymidine incorporation above
basal levels.
The response to anti-TGF-p antibody in the experiments
given in Figure 5 suggest that the growth inhibitory effect of
high glucose is predominantly, but not totally, attributable to
endogenous TGF-/3 bioactivity. It is possible that doses higher
than 30 sg/ml of the antibody may be required for total
neutralization.
— 1.5
a,
>
z
EciU-
I-
a)>4-c
0.5
2.5pg 10g 2.5sg 10pg
Fig. 3. Effect of media glucose concentration on TGF-131 mRNA
levels. A. Mouse proximal tubule cells were cultured for 48 hours in
media containing 100 mg/dl glucose (open bar) or 450 mg/dl glucose(hatched bar). RNA dot-blot hybridization with the TGF-/31 cDNA
probe was then performed, followed by stripping the filter and reprob-
ing with the control OAPDH probe. The ratio of the densitometric
signal for TGF-p1 mRNA to that of GAPDH was determined. For cells
cultured in 100 mg/dl glucose, this ratio was assigned a value of unity.
The relative TGF-/31 mRNA level (normalized for GAPDH mRNA
level) was significantly higher (* P < 0.02, N = 4) in cells grown in high
versus normal glucose media. B. Representative autoradiographs from
a single experiment of dot-blots hybridized with TGF-/31 cDNA and,
after stripping, with GAPDH cDNA. The upper dots are for cells
cultured in 100 mg/dl glucose (Gl00) and the lower dots for cells
cultured in 450 mgldl glucose (G450). As indicated, each dot was loaded
in duplicate with either 2.5 or 10 tg of total RNA for each culture
condition.
Discussion
Our studies suggest that the inhibition in cell proliferation
induced by high glucose concentration is largely mediated by
the increased TGF-/3 activity in proximal tubule cells and a
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Fig. 4. Demonstration of the neutralizing effect of anti-TGF-f3 anti-
body against exogenously administered TGF-p. Mouse proximal tubule
cells were cultured for 72 hours in media containing 450 mg/dl glucose
with 40 M of exogenous TGF-/3 alone (first bar), or with the addition of
anti-TGF-fl neutralizing antibody (second bar) or control rabbit anti-
sheep IgG (third bar). The medium containing 450 mg/dl glucose
without any supplements is taken as control in this set of experiments.
Note that anti-TGF-/3 antibody partially restores the antiproliferative
effect of TGF-/3, but that the control rabbit anti-sheep IgG had no effect.
Glucose, mg/dI
Fig. 5. Effect of anti-TGF-$ antibody on mouse proximal tubule cell
proliferation. Cells were cultured for 48 hours in serum-free media
containing 100 or 450 mg/dl of D-glucose with the addition of anti-
TGF-/3 antibody at 30 g/ml (solid bars), control normal rabbit IgG at 30
i.g/ml (hatched bars) or vehicle (open bars). Results are expressed as
the mean absolute cpm of [3H]-thymidine incorporation SE for N = 6
replicates.
Fig. 6. Effect of anti-TGF-f3 antibody on mouse proximal tubule cell
proliferation. Cells were cultured for 48 hours in serum-free media
containing 100 mg/dl or 450 mg/dl of D-glucose with the addition of 10
tg/ml of anti-TGF-/3 antibody (aTGF-/3) (solid bars) or control rabbit
anti-sheep IgG (hatched bars). Results are expressed as percent prolif-
eration compared to cells grown without the addition of antibody. A.
Cells cultured in serum-free media with a D-glucose concentration of
100 mgldl (N = 6). No significant effect on proliferation was seen with
either antibody. B. Cells cultured in serum-free media with a D.glucose
concentration of 450 mgldl. TGF-/3 antibody, but not control rabbit
anti-sheep IgG, increased cell proliferation. Values are expressed as the
mean SE for N = 6 experiments. * P < 0.05 comparing the effect of
anti-TGF-/3 antibody to control IgG for cells cultured in 450 mg/dl of
D-glucose.
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concurrent increase in the steady state levels of TGF-p,
mRNA. These observations raise the possibility that TGF-/3
may mediate in an autocrine fashion some of the effects of high
glucose concentrations on proximal tubule cells.
The growth inhibitory effects of TGF-13 have been confirmed
in a wide variety of epithelial cells as well as in most renal cell
lines examined [5}. In the glomerulus, TGF-/3 inhibits the
proliferation of endothelial, epithelial [13] and mesangial cells
[22, 23], although in mesangial cells, one group has reported
that inhibition occurs if the cells are plated at low density, and
stimulation if the cells are plated at high density [13]. In renal
tubular epithelial cells, our results are similar to those found in
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rabbit proximal tubule cells [7] and in a mouse collecting tubule
cell line (Ziyadeh, unpublished data).
The nuclear mechanisms responsible for the inhibitory effect
of TGF-J31 on cell proliferation are not fully characterized, but
are believed to be partly related to changes in the expression of
the c-myc proto-oncogene or to the state of phosphorylation of
the protein product of the retinoblastoma gene (pRB) [24, 25].
These two actions may be related. In MvlLu lung epithelial
cells, TGF-f31 prevents phosphorylation of pRB leading to the
arrest of the cells in the late GI phase of the cell cycle [261;
under-phosphorylation of the RB gene product prevents pro-
gression to later phases of the cell cycle. Also, virally trans-
formed skin keratinocytes which produce specific DNA tumor
virus oncoproteins that can bind to the pRB are resistant to the
inhibitory effects of TGF-/3 on growth inhibition and c-myc
levels [27]. Keratinocytes that produce mutant viral proteins
that are unable to bind to the pRB, however, demonstrate
inhibition of proliferation when exposed to TGF-/3 [27].
Previous studies have shown that epithelial cells derived from
the African green monkey kidney (BSC-1) produce both
TGF-J31 and TGF-/32 [8]. Also, in the glomerulus of the rat
kidney, both TGF-/31 and TGF-/32 are produced, with protein
levels several-fold higher than those found in whole kidney [28].
We confirmed the presence of TGF-p1 mRNA in nonglomerular
tissue by demonstrating the 2.5-kb TGF-/31 transcript by North-
ern analysis in mouse proximal tubule cells (Fig. 2). In addition,
receptors for TGF-/3 have been located in most organ systems
examined [3, 4], although the number of receptors per cell can
vary widely [4]. In the kidney, receptors have been identified on
glomerular endothelial, mesangial and epithelial cells [131 as
well as on kidney fibroblasts and tubular epithelial cells [4]. The
concentration of TGF-/3 which yields a half maximal inhibition
of cellular proliferation (IC0 = 20 to 30 pM; Fig. 1) implies that
the response of proximal tubule cells to TGF-/3 likely involves
the interaction with high affinity receptors. In other cell systems
studied, the dissociation constant (Kd) for the binding of TGF-j3
to its receptors is usually within the same picomolar range [41.
Northern analysis and dot-blot hybridization of mRNA iso-
lated from MCT cells grown in normal and high 2lucose media
demonstrated that the steady state level of TGF-/31 IURNA is
increased in the presence of high glucose media. Furthermore,
by using an antibody which neutralizes the activity of TGF-/31
and TGF-f32 [29], we reversed the inhibition of proliferation
caused by high glucose media. Both these results support the
hypothesis of the interaction between the high glucose effect
and TGF-f31 (or TGF-32) expression. The reduction in basal
levels of cellular proliferation which is observed in the high
glucose medium becomes prominent at 48 hours in culture. This
lag period appears to correspond to the time which is required
to stimulate TGF-/3 mRNA levels.
The increased levels of TC'F-/31 mRNA induced by high
glucose concentration could be due to an increased rate of gene
transcription and/or due to decreased mRNA degradation or
message stabilization. We did not attempt to determine which
of these mechanisms may be applicable in our system. How-
ever, evidence suggests that both mechanisms may operate
concurrently as high glucose levels were found to stimulate the
transcription rate of collagen genes in MCT cells [16] as well as
stabilize the message of the insulin gene in /3-islets of the
pancreas [30].
The conclusion that the reduction in basal levels of thymidine
incorporation in high glucose media could be attributed to
increased endogenous TGF-J3 activity is indirectly supported by
data in Figure 1. As the concentration of exogenous TGF-J3 was
increased, the difference in thymidine incorporation between
high and normal glucose media became progressively smaller.
This observation suggests the presence of a higher endogenous
level of growth-inhibitory activity in the high glucose media as
further dosing of exogenous TGF-f3 produced little additional
inhibition of proliferation. The profile of these dose-response
curves (Fig. 1) thus provides indirect evidence that the cells
cultured in high glucose media elaborate higher basal levels of
TOF-/3-like inhibitory activity.
The studies involving the anti-TGF-13 antibody provide strong
evidence that the conditioned medium of MCT cells grown in
450 mg/dl glucose contains quantities of bioactive TGF-f3 which
are sufficient to alter basal levels of DNA synthesis as deter-
mined by tritiated thymidine incorporation. It should be noted
here that the antibody only binds to the active rather than the
latent form of TGF-/3 (R & D, manufacturer's data file).
However, since the antibody binds to at least two isoforms of
the cytokine, TGF-f31 and TGF-/32 [29], its neutralizing proper-
ties in the conditioned media may be attributed to the binding of
one or more TGF-/3 isoforms. Moreover, while the observations
on the antibody action support the conclusion that high glucose
concentrations induce increased TGF-f3 bioactivity, they do not
point to a specific mode of activation. The increased levels of
bioactive TGF-/3 may reflect increased synthesis, decreased
degradation or an increased conversion of latent to active
forms. The finding of increased mRNA levels implies an in-
creased rate of cytokine synthesis, but other mechanisms of
TGF-/3 activation cannot be excluded. Additionally, our studies
do not exclude the possibility that a minor component of the
growth inhibitory effect of high glucose may be attributed to
induction of inhibitory factors other than TGF-fJ and/or inhibi-
tion of stimulatory factors.
Cellular or nuclear mechanisms by which elevated ambient
glucose increases TGF-/3 levels are unknown but several pos-
sibilities exist. First, high glucose levels increase the activity of
the polyol pathway with subsequent alterations in cellular
myo-inositol metabolism in a number of target tissues [31],
including kidneys of diabetic rats [32] and in MCT cells [33].
For example, we have found that the addition of 800 M
myo-inositol to MCT cells grown in high glucose media restores
proliferation to levels seen in normal glucose media [34]. These
changes in proliferation are associated with parallel effects on
collagen gene expression as myo-inositol supplementation re-
duces the glucose-stimulated secretion and mRNA levels of
type I and type IV collagen [34]. A second mechanism of action
by which elevated glucose levels may act involves the non-
enzymatic glycation of extracellular or intracellular proteins
[31, 35]. Non-enzymatic glycation could alter the structure of
receptors and/or cellular regulatory proteins and thus influence
TGF-p synthesis or bioactivity.
Other factors can also increase TGF-/3 mRNA levels includ-
ing TGF-/31 itself through self-induction [36]. Moreover, an
inhibitory system regulating TGF-f3 activity has been described.
Decorin, a chondroitin/dermatan sulphate proteoglycan, is pro-
duced by many cell lines and its synthesis can be induced by
TGF-/3 [10, 11, 37]. In turn, decorin can bind to TGF-/3, thus
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neutralizing TGF-/3 activity [38]. It is possible that ambient
glucose could interfere with decorin production or alter the
decorin molecule through nonenzymatic glycation, thereby
modulating TGF-j3 action.
The relevance of these in vitro findings to the problem of
diabetic nephropathy remains to be elucidated. In early diabe-
tes, the kidney enlarges predominantly through cellular hyper-
trophy [39]; previous studies have shown that TGF-/3 induces
hypertrophy in renal proximal tubule cells in vitro [40].
Whether the hypertrophy seen in vivo is, at least in part, the
result of TGF-f3 action in response to hyperglycemia remains to
be tested. In MCT cell cultures, high ambient glucose levels
appear to be a sufficient stimulus to promote cellular hypertro-
phy [16]. TGF-/3 may also transform a mitogenic stimulus into a
hypertrophic one [40]. After various forms of renal injury, renal
tubular cell proliferation becomes an important component of
the regenerative process. It is tempting to speculate that in
diabetic nephropathy, the activation of intra-renal TGF-/3 may
impair this regenerative process and thus delay the recovery
phase of acute renal failure.
In experimental models of renal injury, TGF-/3 has been
implicated in the genesis of fibrotic lesions caused by the
administration of antiglomerular basement membrane antibody
[14] or antithymocyte serum [15]. A role for TGF-J3 in renal
fibrogenesis of various disease states including diabetes also
deserves additional studies. In the diabetic kidney, the patho-
logic changes in the glomerulus [31] and tubulointerstitium [41]
may be mediated by increased synthesis and decreased degra-
dation of extracellular matrix (ECM) components; these
changes, particularly in the glomerular mesangium, are cone-
lated with a decline in glomerular filtration rate [31, 42, 43].
Also, interstitial fibrotic changes are common in advanced
diabetic nephropathy [41], and the degree of fibrosis is directly
related to the serum creatinine level [43, 44]. This increase in
ECM components could be due, at least in part, to increased
expression of TGF-f3. For example, in normal rat kidney (NRK)
cells, TGF-f3 stimulates collagen and fibronectin synthesis and
the level of mRNA for collagen types I, III and V and
fibronectin. TGF-J3 also inhibits the breakdown of ECM com-
ponents by stimulating the synthesis of protease inhibitors and
decreasing the synthesis of several proteases, including transin/
stromeolysin, serine and thiol protease and plasminogen acti-
vator [9]. Thus, it is possible that hyperglycemia leads to
increased TGF-f3 expression, which participates in the in-
creased synthesis of ECM components in tubules and glomeruli
of the diabetic kidney.
In summary, elevated glucose levels in cultured medium of
proximal tubule cells modulate the expression and the respon-
siveness to specific autocrine or paracrine growth-regulatory
factors. In a previous study, we demonstrated that high glucose
potentiated the cellular hypertrophogenic response to exoge-
nously added angiotensin II [45]. In the present study, we
demonstrate that the growth inhibitory effect of elevated glu-
cose levels in culture medium of mouse proximal tubule cells
appears to be mediated by the increased production of endog-
enous TGF-/3. This autocrine function of TGF-f3 provides for a
novel mechanism of action through which ambient glucose
influences certain target cells.
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